| Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. | |
| | |
MedLine Citation:
|
PMID: 21424611 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Botulinum toxin (BTA) is a safe and effective therapeutic tool for many neurological conditions but few studies have investigated its real cost in neurological practice. We evaluated the daily cost of botulinum toxin type A (BTA) treatment through a cost effectiveness analysis alongside a prospective study of BTA injections at a French University Hospital over a 2-year follow-up period. The data of 3,108 BTA injections performed in 870 adult patients presenting with dystonia, facial hemispasm, or spasticity were entered in the database. Patients were questioned at each visit about the subjective effectiveness of the previous injection. The daily cost of BTA treatment was calculated as the ratio of each session's cost (including all additional costs) to the duration of subjective efficacy. The subjective rating of efficacy duration was 17.3 ± 7.7 weeks for facial hemispasm, 15.4 ± 7.7 for blepharospasm, 14.3 ± 6.7 for cervical dystonia, 14.5 ± 7.8 and 14.1 ± 7.4 weeks for upper and lower limb spasticity, respectively. The daily cost of BTA injections was 0.57 ± 0.20 <euro> for facial hemispasm, 0.95 ± 0.30 <euro> for blepharospasm, 2.85 ± 0.86 <euro> for cervical dystonia, 3.38 ± 1.49 <euro> and 3.62 ± 1.81 <euro> for upper and lower limb spasticity, respectively. When associated costs were considered, the daily cost of BTA injections was clearly increased (45-93%) in limb spasticity or rigidity but remained only modestly increased (15-37%) in other indications. These results obtained in a large cohort of patients show that BTA treatment has a low daily cost for a long-lasting effect, with a daily cost/benefit ratio that greatly depends on the indications. |
| | |
Authors:
|
Pierre Burbaud; Camille Ducerf; Emmanuelle Cugy; Jean-Louis Dubos; François Muller; Dominique Guehl; Patrick Dehail; Didier Cugy; Nicholas Moore; Alain Lagueny; Pierre-Alain Joseph |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-3-20 |
Journal Detail:
|
Title: Journal of neurology Volume: - ISSN: 1432-1459 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-3-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0423161 Medline TA: J Neurol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Clinical Neurophysiology, Centre Hospitalier Pellegrin, Place Amélie-Rabat-Léon, 33076, Bordeaux, France, Pierre.Burbaud@chu-bordeaux.fr. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relati...
Next Document: Long-term outcome after traumatic anterior dislocation of the hip.